Cooley LLP advised Neurocrine Biosciences on its licensing and collaboration agreement with Xenon Pharmaceuticals to develop first-in-class treatments for epilepsy.
Neurocrine will pay Xenon $50 million – $30 million upfront in cash and a $20 million equity investment – and up to $1.7 billion in additional development, regulatory and commercial milestone payments.
Under the agreement, Neurocrine gains an exclusive license to XEN901, a clinical-stage drug to treat pediatric patients with SCN8A developmental and epileptic encephalopathy and other forms of epilepsy, including focal epilepsy, as well as the rights to pre-clinical compounds under development to treat the disease. The agreement also includes a multi-year research collaboration to discover, identify and develop additional novel inhibitors.
Neurocrine, whose securities trade on the Nasdaq Global Select market under the symbol “NBIX,” is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.
Cooley lawyers Kay Chandler (Picture), Jason Kent and Rena Kaminsky led the team advising Neurocrine.
Law Firms: Cooley LLP;
Clients: Neurocrine Biosciences, Inc.;